img

Integrated Drug–Device Clinical Trials: Strategy, Operations, and Regulatory Pathways

Course Description

Integrated drug–device clinical trials present unique operational, regulatory, and strategic challenges that go well beyond traditional drug-only or device-only studies. These trials require seamless coordination across regulatory frameworks, cross-functional teams, vendors, and clinical sites—often under tight timelines and heightened regulatory scrutiny.

This hands-on, operations-focused course is designed to equip clinical research professionals with the practical tools, strategies, and decision-making frameworks needed to successfully plan, manage, and execute integrated drug–device trials. While key FDA and Health Canada regulatory concepts are covered, the emphasis is on real-world trial operations, risk management, and execution strategies, not regulatory theory.

Participants will explore how integrated trials differ from standalone drug or device studies, where teams commonly fail, how regulators think about these studies, and how to proactively mitigate risks.

Special Feature: Expert panel on FDA & Health Canada device submissions (45–60 min)

Course at a Glance

2-Day Live In-Person Workshop
2 Full Days of Classroom-based learning

Intensive, instructor-led sessions

May 23 & May 30, 2026

Upcoming Classroom Workshop

9:00 AM - 4:00 PM EST

Small-group, live instructor-led sessions

Price : $1995.00 USD
location Created with Sketch Beta.
Location:

Lionhead Golf Mississauga Road – Ontario

certificate-ribbon-solid
Certificate of Completion from CRTA

Recognized professional credential

Included Perks:

Complimentary Lunches & Coffee breaks

Faculty Director: Luana Torres
Limited Seats - Secure Your Spot Early!

Learning Objectives

By the end of this course, participants will be able to:

  • Distinguish integrated drug–device trials from drug-only and device-only clinical trials from an operational and management perspective
  • Identify early strategic decisions that impact regulatory pathway selection, trial design, and operational complexity
  • Understand how FDA and Health Canada regulate combination products and how those frameworks influence trial execution
  • Design operationally feasible study plans that account for device lifecycle, software updates, and investigational drug supply
  • Anticipate common regulatory, operational, and quality pitfalls in integrated trials
  • Manage cross-functional teams spanning clinical, regulatory, engineering, quality, and manufacturing
  • Develop monitoring, risk management, and vendor oversight strategies specific to integrated trials
  • Apply best practices for documentation, data integrity, and inspection readiness

Who Should Attend

This course is ideal for professionals involved in planning, managing, or overseeing integrated clinical trials, including:

  • Clinical Operations Managers and Directors
  • Clinical Trial Managers and Project Managers
  • Clinical Research Associates (CRAs) and Lead Monitors
  • Biotech and MedTech professionals transitioning into combination product trials
  • Quality, Compliance, and Risk Management professionals
  • Startups and scale-ups professionals running early to mid-phase integrated trials

Prerequisite: Basic understanding of clinical trial conduct, basic regulatory understanding and good GCP-level knowledge.

Course Outline

Day 1 – Strategy, Design, and Operational Foundations

Module 1: Introduction to Integrated Drug–Device Trials (Why These Trials Are Different—and Harder)

  • What defines an integrated drug–device clinical trial
  • Common scenarios: drug + delivery device, drug + diagnostic, SaMD + therapeutic
  • Key differences - drug-only and device-only trials
  • Why operational failures often occur early

Interactive Activity: Group discussion: "What would break first?" — identifying early operational weak points


Module 2: Regulatory Landscape—What Operations Teams Need to Know (FDA & Health Canada – practical, not theoretical)

  • Overview of FDA combination product framework
  • Health Canada approach to combination products
  • Who is the "lead" regulator, and why does it matter operationally
  • IND, IDE, CTA, ITA – what operations teams must track
  • How regulatory pathway decisions impact timelines, monitoring, and documentation

Module 3: Trial Design & Protocol Considerations for Integrated Studies (Highly applied – less theory, more execution)

  • Designing protocols that align drug and device development timelines
  • Device usability, training, and human factors considerations
  • Software updates, version control, and protocol amendments
  • Managing endpoints tied to both drug efficacy and device performance
  • Site burden and feasibility considerations

Interactive Activity: Protocol risk assessment: identifying design elements that increase operational complexity


Module 4: Operational Planning & Cross-Functional Execution

  • Aligning clinical operations, engineering, regulatory, and quality teams
  • Managing investigational product supply (drug + device)
  • Site selection and activation challenges unique to integrated trials
  • Vendor oversight: CROs, device manufacturers, software vendors
  • Communication strategies to avoid siloed execution

Scenario-Based Activity: Cross-functional conflict simulation and resolution strategies

Day 2 – Execution, Oversight, and Regulatory Reality

Module 5: Monitoring & Oversight in Integrated Drug–Device Trials

  • How monitoring differs from drug-only trials
  • Device accountability, traceability, and training verification
  • Monitoring device performance and software-related deviations
  • Data integrity risks unique to integrated trials
  • Red flags CRAs and study teams must escalate early
  • Risk-based monitoring strategies for integrated studies

Module 6: Quality, Risk Management, and Inspection Readiness

  • Common inspection findings in integrated trials
  • Documentation pitfalls
  • Change management and CAPA considerations
  • Preparing for FDA and Health Canada inspections – Operations focused
  • Inspection readiness as an ongoing operational process

Module 7: Discussion Panel – Regulatory Pitfalls & Red Flags (45–60 minutes)

Panel Focus Areas:

  • Most common FDA and Health Canada submission pitfalls
  • Red flags regulators notice immediately
  • Gaps between clinical operations and regulatory expectations
  • Lessons learned from real submissions
  • How operations teams can proactively prevent regulatory delays

Live Q&A


Module 8: Closing Session – Knowledge Check & Integration

  • Interactive quiz covering key concepts from both days
  • Group reflection: "What will you do differently on your next trial?"
  • Practical takeaways and tools for immediate application
  • Open Q&A
Interactive Activities (Summary)

Throughout the course, participants will engage in:

  • Case-based discussions using real-world trial scenarios

  • Protocol and operational risk assessments

  • Monitoring simulations and red flag identification

  • Cross-functional problem-solving exercises

  • Live panel Q&A

  • Interactive knowledge quiz and applied discussion

Luana Torres
Faculty Director’s Bio:

Luana Torres

PhD, BScPT

Luana Torres is a senior clinical research leader with over 12 years of experience managing global clinical trials across biotech, MedTech, and academic research environments.

Her expertise spans clinical operations, trial design, monitoring oversight, regulatory strategy, cross-functional leadership, vendor, budget negotiation and inspection readiness. She has led high-complexity programs in oncology, neurodegenerative diseases, surgery, AI-driven medical devices and combination product trials.

With a strong academic foundation—including a PhD and postdoctoral training in Biotechnology – she is also an accomplished educator and mentor. Luana has authored numerous peer-reviewed publications, grants, and book chapters, and is recognized for translating regulatory and operational complexity into practical, real-world guidance for clinical research professionals.

Currently serving as a Clinical Operations and Development Consultant, she partners with biotech, MedTech, digital health, and academic teams to transform innovative concepts into strategically designed, operationally robust and inspection-ready clinical programs.

Become Our Faculty Director Today

Be part of a global network of virtual and in-person workshops

Global Pharma companies and CROs employing our graduates

Global Pharma companies and CROs
employing our graduates